Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Cynapsus Thera Cm Sh (CYNA)

Cynapsus Thera Cm Sh (CYNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Cynapsus Thera Cm Sh 828 Richmond Street West Toronto A6 M6J 1C9

www.cynapsus.ca P: 416-703-2449

Description:

Cynapsus Therapeutics, Inc. is a specialty pharmaceutical company engaged in developing a drug used to treat the symptoms of Parkinson's disease. The Company's drug candidate, APL-130277, is a reformulation of apomorphine, which is approved in an injection formulation to rescue patients from `off` episodes. Cynapsus Therapeutics Inc. is headquartered in Toronto, Canada.

Key Statistics

Overview:

Market Capitalization, $K 532,220
Shares Outstanding, K 13,150
Annual Sales, $ 0 K
Annual Net Income, $ -21,530 K
60-Month Beta 0.49
% of Institutional Shareholders 56.62%

Growth:

1-Year Return 182.68%
3-Year Return 552.40%
5-Year Return 0.00%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Next Earnings Date 11/10/16
Earnings Per Share ttm -2.26
EPS Growth vs. Prev Qtr -22.06%
EPS Growth vs. Prev Year 31.97%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-16 on 05/21/15

CYNA Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -35.81%
Return-on-Assets % -32.75%
Profit Margin % 0.00%
Debt/Equity 4.96
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 8.70
Book Value/Share 0.00
Interest Coverage 0.00
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar